Reneo Pharmaceuticals, Inc.
NASDAQ: RPHM0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Gregory J. Flesher
- Employees
- 8
- Headquarters
- Irvine, United States
- IPO year
- 2021
- Market cap
- $60.8M
- Website
- https://reneopharma.com
Loading RPHM…
Loading profile data…Frequently asked questions about RPHM
What does Reneo Pharmaceuticals, Inc. (RPHM) do?
Reneo Pharmaceuticals, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to creating therapies for individuals suffering from uncommon inherited mitochondrial disorders. The company's lead candidate, REN001, functions as a selective peroxisome proliferator-activated receptor delta agonist. This compound is currently u...
Where does RPHM trade?
Reneo Pharmaceuticals, Inc. (RPHM) trades on the NASDAQ Global Market.
What sector is RPHM in?
Reneo Pharmaceuticals, Inc. (RPHM) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Reneo Pharmaceuticals, Inc.?
Gregory J. Flesher is the chief executive officer of Reneo Pharmaceuticals, Inc. (RPHM).
Where is Reneo Pharmaceuticals, Inc. headquartered?
Reneo Pharmaceuticals, Inc. is headquartered in United States.
Does RPHM pay a dividend?
Reneo Pharmaceuticals, Inc. (RPHM) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did RPHM go public?
Reneo Pharmaceuticals, Inc. (RPHM) completed its initial public offering in 2021.